MedTrace Logo

Antibodies Response to mRNA Vaccine Against Covid-19

NCT04733807 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2021-05-11

No results posted yet for this study

Summary

Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the moment is the mRNA-based BNT162b2 and is given to Hospital employers. The investigators undertake this study to monitor IgG evolution after vaccination in the participant hospital settings, which includes 500 subjects.

Conditions

Interventions

BIOLOGICAL

BNT162b2 mRNA Covid-19 Vaccine

Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.

Sponsors & Collaborators

  • ICOT University Hospital

    collaborator UNKNOWN

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Luigi Iuliano, M.D. · University of Roma La Sapienza

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-28
Primary Completion
2021-07-31
Completion
2022-02-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04733807 on ClinicalTrials.gov